Of interest, treatment of PAECs with either BMP9 or BMP10, both in the physiologically relevant prodomain-bound forms and at physiologically relevant concentrations, can supress the expression of the INHBB gene which encodes ActB (Figure 3) [90], in agreement with a beneficial effect of a BMP9 agonist approach for treating PAH. Here, BMP10 is linked to pulmonary arterial hypertension.